Vignaux O, Allanore Y, Meune C, Pascal O, Duboc D, Weber S, Legmann P, Kahan A
Services de Radiologie A, Hôpital Cochin, AP-HP, Université Paris V, 75014 Paris, France.
Ann Rheum Dis. 2005 Sep;64(9):1268-73. doi: 10.1136/ard.2004.031484. Epub 2005 Feb 11.
Primary myocardial involvement due to microcirculation impairment is common in systemic sclerosis (SSc). Cardiovascular magnetic resonance imaging (MRI) and tissue Doppler echocardiography (TDE) were recently shown to be more sensitive than conventional methods for the respective assessment of myocardial perfusion and contractility. Previous studies have suggested that dihydropyridine-type calcium channel blockers mitigate both myocardial perfusion and function abnormalities.
To investigate the effects of nifedipine on myocardial perfusion by MRI and on contractility by TDE, in patients with SSc.
18 patients with SSc without clinical heart failure and with normal pulmonary arterial pressure (14 women, 4 men; mean (SD) age 59 (9) years; mean (SD) disease duration 7 (4) years, 10 with diffuse and 8 with limited cutaneous forms) were prospectively evaluated. The MRI perfusion index, determined from time-intensity curves, and systolic and diastolic strain rate determined by TDE were assessed at baseline, after a 72 hour vasodilator washout period, and after 14 days of oral treatment with nifedipine 60 mg/day.
Nifedipine treatment led to a significant increase in the MRI perfusion index (mean (SD) 0.26 (0.07) v 0.19 (0.05) at baseline, p = 0.0003) and in systolic and diastolic strain rate (2.3 (0.6) v 1.5 (0.4) s(-1) at baseline, p = 0.0002, and 4.2 (1.6) v 3.0 (1.2) at baseline, p = 0.0003, respectively).
Fourteen days of treatment with nifedipine simultaneously improves myocardial perfusion and function, as evaluated by highly sensitive and quantitative methods.
微循环障碍导致的原发性心肌受累在系统性硬化症(SSc)中很常见。最近研究表明,心血管磁共振成像(MRI)和组织多普勒超声心动图(TDE)在评估心肌灌注和收缩性方面比传统方法更敏感。先前的研究提示,二氢吡啶类钙通道阻滞剂可减轻心肌灌注和功能异常。
研究硝苯地平对SSc患者心肌灌注(通过MRI评估)和收缩性(通过TDE评估)的影响。
前瞻性评估18例无临床心力衰竭且肺动脉压正常的SSc患者(14例女性,4例男性;平均(标准差)年龄59(9)岁;平均(标准差)病程7(4)年,10例为弥漫性皮肤型,8例为局限性皮肤型)。在基线、72小时血管扩张剂洗脱期后以及口服硝苯地平60mg/天14天后,评估由时间-强度曲线确定的MRI灌注指数以及由TDE确定的收缩期和舒张期应变率。
硝苯地平治疗使MRI灌注指数显著增加(基线时平均(标准差)为0.26(0.07),治疗后为0.19(0.05),p = 0.0003),收缩期和舒张期应变率也显著增加(基线时分别为2.3(0.6)和1.5(0.4)s⁻¹,p = 0.0002;基线时分别为4.2(1.6)和3.0(1.2),p = 0.0003)。
通过高灵敏度和定量方法评估,硝苯地平治疗14天可同时改善心肌灌注和功能。